share_log

中國中藥:根據《收購守則》規則22作出的交易披露

TRAD CHI MED: Disclosure of Dealings under Rule 22 of the Takeovers Code

HKEX ·  Sep 27 05:11

Summary by Moomoo AI

2024年9月27日,根據香港《公司收購及合併守則》第22條規則,中國中藥控股有限公司(簡稱「中國中藥」)披露了一系列股份交易。交易由Integrated Core Strategies (Asia) Pte. Ltd.於9月25日進行,包括賣出總計978,000股,並買入總計1,484,000股。交易後,Integrated Core Strategies (Asia) Pte. Ltd.持有的中國中藥股份百分比從5.0172%變動至5.0462%。Integrated Core Strategies (Asia) Pte. Ltd.是中國中藥的第(6)類別聯繫人,並且這些交易是為其本身帳戶進行的。
2024年9月27日,根據香港《公司收購及合併守則》第22條規則,中國中藥控股有限公司(簡稱「中國中藥」)披露了一系列股份交易。交易由Integrated Core Strategies (Asia) Pte. Ltd.於9月25日進行,包括賣出總計978,000股,並買入總計1,484,000股。交易後,Integrated Core Strategies (Asia) Pte. Ltd.持有的中國中藥股份百分比從5.0172%變動至5.0462%。Integrated Core Strategies (Asia) Pte. Ltd.是中國中藥的第(6)類別聯繫人,並且這些交易是為其本身帳戶進行的。
On September 27, 2024, in accordance with Rule 22 of the Hong Kong Code on Takeovers and Mergers, trad chi med Holdings Limited (referred to as "trad chi med") disclosed a series of share trades. The trades were conducted by Integrated Core Strategies (Asia) Pte. Ltd. on September 25, including selling a total of 978,000 shares and buying a total of 1,484,000 shares. After the trades, the percentage of trad chi med shares held by Integrated Core Strategies (Asia) Pte. Ltd. changed from 5.0172% to 5.0462%. Integrated Core Strategies (Asia) Pte. Ltd. is a Category (6) connected person of trad chi med, and these trades were conducted for its own account.
On September 27, 2024, in accordance with Rule 22 of the Hong Kong Code on Takeovers and Mergers, trad chi med Holdings Limited (referred to as "trad chi med") disclosed a series of share trades. The trades were conducted by Integrated Core Strategies (Asia) Pte. Ltd. on September 25, including selling a total of 978,000 shares and buying a total of 1,484,000 shares. After the trades, the percentage of trad chi med shares held by Integrated Core Strategies (Asia) Pte. Ltd. changed from 5.0172% to 5.0462%. Integrated Core Strategies (Asia) Pte. Ltd. is a Category (6) connected person of trad chi med, and these trades were conducted for its own account.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more